1 / 15

Naloxone Market Analysis | CMI

Read here the latest updates on the Naloxone Market Analysis published by CMI team

Shweta2707
Download Presentation

Naloxone Market Analysis | CMI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. NALOXONE MARKET ANALYSIS • Naloxone Market, by Drug Type (Branded and Generic), by Administration (Intranasal Administration, Intramuscular Administration, and Intravenous Administration), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Geography - Size, Share, Outlook, and Opportunity Analysis 2018-2026 • The global naloxone market size was valued at US$ 310.2 Mn in 2017, and is expected to witness a CAGR of 11.4% over the forecast period (2018 – 2026).

  3. Frequent launches and approvals of novel naloxone products is expected to fuel the global Naloxone Market growth • Increasing launches and approval of novel naloxone products by various regulatory bodies is expected to be a major factor aiding in growth of the market over the forecast period. For instance, in January 2017, the U.S. Food and Drug Administration (FDA) approved Adapt Pharma Inc.’s NARCAN Nasal Spray 2 mg formulation for emergency treatment of known or suspected opioid overdose. In 2016, Mylan N.V. launched its naloxone hydrochloride injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. It is therapeutically equivalent to the naloxone hydrochloride injection 0.4 mg/mL, of Hospira Inc. In September 2017, Mundipharma International Limited received approval from European Medicines Agency (EMA) for its product (intranasal naloxone 1.8 mg) to use in emergency reversal of opioid overdose.

  4. Figure 1. Global Naloxone Market Share (%), By Strength, 2018–2026

  5. Increasing drug abuse in key regions is expected to increase demand for its treatment drugs • Increasing cases of opioid overdose is expected to increase demand for naloxone products during emergency treatments which in turn will positively drive the global naloxone market growth. For instance, according to the data published by the U.S. Department of Health and Human Services (HHS) in 2016, around 11.5 million people misuse prescription drugs and around 948,000 people use heroin. According to the data published by National Institute on Drug Abuse, 2018, in the U.S., everyday over 115 people die due to opioid overdosing. According to same source, in the U.S. opioid overdose increased by 30% from July 2016 through September 2017 in 52 areas in 45 states.

  6. Figure 2. Global Naloxone Market Share (%), By Region, 2026

  7. Favorable reimbursement scenarios for naloxone products is also expected to aid in market growth • Reimbursement scenario for drugs play a major role in adoption of high cost products in developed regions such as North America and Europe. Therefore, favorable reimbursements for naloxone products is expected to support the adoption of these products. Currently, most types of insurance cover and reimburse for naloxone administered directly in a medical setting. • Furthermore, some states in the U.S. have started covering take-home naloxone. Hence, adoption of take-home naloxone is expected to increase in the near future. For instance, in New York State from January 2014, the state’s Medicaid program began to cover the intramuscular formulation of take?home naloxone.

  8. Market Segment • North America naloxone market is expected to a hold dominant position over the forecast period due to the presence of novel naloxone products such as Narcan nasal spray and EVZIO (naloxone hydrochloride injection), which is still not present in any other region. Furthermore, initiatives taken by various companies and organizations to increase access of naloxone is expected to fuel the market growth. For instance, in February 2018, Loyola Medicine and the Cook County Department of Homeland Security and Emergency Management collaborated, where Loyola Medicine trained police officials to use Narcan in case of opioids overdose. In 2016, Adapt Pharma Limited partnered with Smith Medical Partners, LLC for distribution of free Narcan (Naloxone HCl) nasal spray in all high schools in the U.S.

  9. Furthermore, Europe naloxone market is expected to show significant growth in the near future, owing to increasing approvals of novel naloxone products in the region. For instance, in July 2017, Indivior Inc., a subsidiary of Indivior Plc., received marketing authorization (MA) from French Regulatory Agency ANSM for its new Nalscue naloxone hydrochloride nasal spray indicated for emergency treatment of characterized or suspected opioid overdose in France. • In February 2017, Adapt Pharma Limited filed marketing application for its product Naloxone Hydrochloride (HCl) nasal spray in Europe. Hence, these products when launched in the European market it will drastically fuel market growth in the near future

  10. Regulatory Scenario • In 2016, Therapeutic Goods Administration (TGA) placed naloxone on Schedule 3 when used for the treatment of opioid overdose, thus allowing the over-the-counter (OTC) purchase of naloxone in Australia. • In Europe, many countries allow take-home naloxone due to high rate of opioid overdose in this region. Currently, take-home naloxone programs exists in seven European countries— Denmark, Estonia, Germany, Italy, Norway, Spain, and the U.K. (EMCDDA, 2015c). • According to the data published by Regulatory Affairs Professional Society, naloxone is still not approved by the U.S. FDA as an over-the-counter (OTC) drug. However, some organizations such as Walgreens pharmacies are providing naloxone products over-the-counter in over 5,800 of its 8,200 stores to increase the access of naloxone.

  11. Key Players • Key players operating in the naloxone market include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.

  12. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Reference : https://www.coherentmarketinsights.com/market-insight/naloxone-market-1804

  13. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  14. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  15. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related